Evidence map›Paper›PMID 26752952›Full record

ArticleAnnals of gastroenterology

Changes in serum transforming growth factor-β1 levels in chronic hepatitis C patients under antiviral therapy.

Ioanna Kotsiri, Emilia Hadziyannis, Anastasia Georgiou, Maria-Vasiliki Papageorgiou, Ioannis Vlachogiannakos, George Papatheodoridis

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis.Cold Spring Harbor perspectives in medicine · 2020
    Review
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ioanna KotsiriDepartment of Gastroenterology, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital of Athens (Ioanna Kotsiri, Anastasia Georgiou, Maria-Vasiliki Papageorgiou, Ioannis Vlachogiannakos, George Papatheodoridis); 2nd Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Hippokratio General Hospital of Athens (Ioanna Kotsiri, Emilia Hadziyannis), Greece.
Emilia Hadziyannis2nd Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Hippokratio General Hospital of Athens (Ioanna Kotsiri, Emilia Hadziyannis), Greece.
Anastasia GeorgiouDepartment of Gastroenterology, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital of Athens (Ioanna Kotsiri, Anastasia Georgiou, Maria-Vasiliki Papageorgiou, Ioannis Vlachogiannakos, George Papatheodoridis).
Maria-Vasiliki PapageorgiouDepartment of Gastroenterology, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital of Athens (Ioanna Kotsiri, Anastasia Georgiou, Maria-Vasiliki Papageorgiou, Ioannis Vlachogiannakos, George Papatheodoridis).
Ioannis VlachogiannakosDepartment of Gastroenterology, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital of Athens (Ioanna Kotsiri, Anastasia Georgiou, Maria-Vasiliki Papageorgiou, Ioannis Vlachogiannakos, George Papatheodoridis).
George PapatheodoridisDepartment of Gastroenterology, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital of Athens (Ioanna Kotsiri, Anastasia Georgiou, Maria-Vasiliki Papageorgiou, Ioannis Vlachogiannakos, George Papatheodoridis).
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral cytokines including transforming growth factor (TGF)-β1 have been suggested to be involved in the pathogenesis of fibrosis in chronic hepatitis C. We examined the changes of TGF-β1 serum levels and their predictive value in patients with chronic hepatitis C under antiviral therapy.

methodsWe included 84 patients with chronic hepatitis C who were treated with pegylated interferon-α and ribavirin between 2008 and 2009. Treatment was given for 24-48 weeks depending on HCV genotype. Serum TGF-β1 levels were measured by an ELISA assay at baseline, at the end of therapy (EOT), and at 6 months after the EOT. Liver fibrosis was evaluated by transient elastography.

resultsOf the 84 patients, 76.2% achieved sustained virological response (SVR), 8.3% responded at the EOT but relapsed during post-therapy follow up (RR) and 15.5% had no response (NR). In all patients, mean TGF-β1 levels were 16,980 pg/mL at baseline and decreased significantly at EOT (12,041 pg/mL) and at 6 months of post-treatment follow up (13,254 pg/mL) (P≤0.001). In particular, mean TGF-β1 levels decreased significantly from baseline to EOT and to six months of post-treatment follow up in patients with SVR and numerically but not significantly in patients with RR or NR. TGF-β1 levels were not associated with the severity of liver stiffness estimated by transient elastography.

conclusionOur data show that TGF-β1 serum levels decrease significantly at the EOT and remain decreased 6 months after the EOT mostly in chronic hepatitis C patients who achieve SVR after pegylated interferon-α and ribavirin combination treatment.

Indexed as

antiviral treatmentelastographyHCVliver fibrosisTGF-β1

Identifiers

PMID26752952
PMCPMC4700851
OpenAlexW2234906334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.